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Background: Cervical cancer is a frequently diagnosed cancer in women worldwide. Despite having easy
preventive and therapeutic approaches, it is an important cause of mortality among women.
Methods: The CRICERVA study is a cluster clinical trial which assigned one of three interventions to the target
population registered in Cerdanyola, Barcelona. Among the 5,707 resident women aged 60 to 70 years in the study
area, women with no record of cervical cytology over the last three years were selected. The study included four
arms: three interventions all including a pre-assigned date for screening visit and i) personalized invitation letter;
ii) adding to i) an informative leaflet; and, iii) in addition to ii) a personalized appointment reminder phone call, and
iv) no specific action taken (control group). Participants were offered a personal interview about social-demographic
characteristics and about screening attitudes. Cervical cytology and HPV DNA test (HC2) were offered as screening
tests. In the case of screening positive in any of these tests, the women were followed up until a full diagnosis
could be obtained. The effect size of each study arm was estimated as the absolute gain in coverage between the
original coverage and the final coverage.
Results: From the intervention groups (4,775 women), we identified 3,616 who were not appropriately screened, of
which 2,560 women answered the trial call and 1,376 were amenable to screening. HPV was tested in 920 women
and cervical cytology in all 1,376. Overall, there was an absolute gain in coverage of 28.8% in the intervention
groups compared to 6% in the control group. Coverage increased from 51.2% to 76.0% in strategy i); from 47.4% to
79.0% in strategy ii) and from 44.5% to 74.6% in strategy iii). Lack of information about the relevance of screening
was the most important factor for not attending the screening program.
Conclusions: The study confirms that actively contacting women and including a date for a screening visit, notably
increased participation in the screening program. Efforts to improve health education in preventative activities are
warranted.
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Cervical cancer is the second most frequently diagnosed
cancer in women worldwide, with at least 500,000 new
cases detected each year [1]. Despite having easy preventive
and therapeutic approaches, this neoplasm continues to
be an important cause of morbidity and mortality among
women, particularly in developing countries where screen-
ing is infrequent or even absent.
In Spain, the age-adjusted (using world population age
structure) incidence rate of invasive squamous cervical
cancer is 6.3 cases per 100,000 women per year [1]. This
incidence has remained constant during the 15 year period
from 1983-1997, but an increase has been observed in the
cohort of women born after 1930-1940, probably due to a
lack of screening coverage [2]. The etiological cause of
cervical cancer is infection by the human papillomavirus
(HPV) [3]. Genotypes 16 and 18 are the most prevalent in
cervical cancer cases within our setting and together with
phenotypes 45, 31, 33, 35, 52, and 58 are responsible for
90% of the cervical cancers reported, with a global preva-
lence of 99.7% [4,5].
The Papanicolau test, which was introduced in the
1960s, led to a reduction of up to 80% in the incidence
and mortality caused by this disease because it enables
early diagnosis of pre-cancerous lesions [6] and it con-
tinues to be the principle diagnostic test used in screening
programs worldwide. One of the limitations of this cyto-
logical test is its low sensitivity, and therefore periodic rep-
etitions are needed. The detection of the HPV has been
thoroughly researched in randomized clinical trials and is
now being recommended as a primary screening tool in
several screening programs [7].
In Spain screening for cervical cancer is largely oppor-
tunistic and cytology based [8]. In Catalonia the protocol
for recommendations of preventive activities for cervical
cancer was initiated in 2006 by the Directive Oncology
Plan (Plan Director de Oncologia) and the Catalan Insti-
tute of Oncology (Institut Catala d‘Oncologia) [9]. In this
region, there are only two studies that have evaluated the
impact of screening among women with invasive cervical
cancer. They reported that between 50% and 80% of
women had not undergone previous cytology tests during
the 10 years prior to cancer diagnosis [10,11]. Thus, an in-
crease in screening coverage should be a priority objective
for those responsible for health care policies, if the inci-
dence of cervical cancer is to be reduced. This screening
should identify and include those women who have not
periodically had cytological tests. Some authors have re-
ported that factors such as ethnic origin, age, education
and socioeconomic level could influence participation in
screening programs [12]. Five possible reasons for women
to not undergo screening are: (a) the perception of vulner-
ability, (b) the benefits of screening are not perceived, (c)
anxiety, (d) confusion, and (e) the fear of cancer, familydifficulties or personal circumstances [12]. In terms of the
factors influencing participation in screening, some au-
thors have suggest the following reasons: the absence of
population-based programs, low sensitization with respect
to preventive attitudes in cohorts of elderly women and,
health care overload in primary care centres [10,13].
In a systematic review from the Cochrane collaboration
[12] evaluating interventions to stimulate women’s partici-
pation in screening programs for this disease, the authors
concluded that invitations and educational interventions
seem to be the most effective ways to increase participa-
tion. In addition, there is sufficient evidence to increase
coverage by using individualized information directed at
the target population [13,14]. There is strong evidence that
call-recall systems (i.e. sms, email or phone calls) are ef-
fective as well (13). Forbes et al. encourages implementing
trials such as the one presented here, to further support
strategies to increase coverage [12].
The upper age limit for population screening is generally
65 years [9]. However, some studies [2,15,16] have ob-
served an increase in the incidence of cancer in women
born in the decade from 1930-1940. The Recommenda-
tions of the Spanish Consensus of 2006 on the secondary
prevention of cervical cancer [2,16] and Resolution 287 of
the European Council (June 10, 2008 Luxemburg), related
to the volume of cancer in the European Union and the
mechanisms to reduce this prevalence [15], recommend
the age of screening be raised to 70 years.
The incidence of and mortality from cervical cancer
are not uniform in terms of age. In the elderly age group
[2] incidence and mortality tend to converge, demon-
strating, on one hand, the worse prognosis of tumors at
advanced ages, and on the other hand, the relative ab-
sence of early diagnoses. It is relevant to take into ac-
count that information campaigns on the prevention of
cancer, and sexual education in schools were inconsist-
ently carried out in Spain and in 80s and 90s of the last
century. Therefore, there is a particular interest and
need to perform studies in this age group.
The CRICERVA project [5] is a population study includ-
ing women aged 30-70 years. The aim of this study was to
determine which of three intervention strategies was the
most effective in terms of screening coverage for cervical
cancer. As a secondary objective we analyzed the factors
associated with screening adherence and coverage.
Adherence was defined as a collaborative response to
both the invitation from the physician to perform an
interview and a medical visit according to appropriate-
ness. In this study we only present data restricted to
women aged from 60-70 years. Any women selected in
this study with a confirmed history of not being appro-
priately screened for cervical cancer were offered a cer-
vical cytology with an HPV DNA test, according to the
standard recommendations.
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The CRICERVA study [5] is a multicenter, randomized,
controlled, community-based cluster clinical trial, with four
arms and performed in the SAP of Cerdanyola, Barcelona,
Spain. It covers a population of 120,293 individuals over
the age of 14 years. This study was approved by the Ethical
Committee of the IDIAP Jordi Gol, and was registered at
the Clinical Trials.gov identifier NCT01373723 on the14th
of June in 2011.
All the women were adequately informed about the
screening procedures and the significance of the results
of both cervical cytology and HPV DNA tests when they
came for the programmed visit. All participants signed
an informed consent.
We targeted all women (N = 3,616) aged from 60 to
70 years of age, living in an area in which we could not
retrieve any cytological test results from their medical
records, or with a cytology test carried out more than
3 years before in women aged 60 to 65 years, or a previ-
ous cytology before the age of 60 if the women were
65 years old or more.
Exclusion criteria
The following exclusion criteria were applied: (a) hysterec-
tomized women with a history of pre-malignant lesions
(AGUS ASCUS, LSIL, HSIL), carcinoma in situ or cervical-
uterine cancer, HIV positive or other causes of immuno-
suppression (since these women follow a specific protocol);
(b) non residents in the area for more than 6 months.
Sample size
The sample size was calculated based on the detection of
a difference in coverage among the intervention group
compared with the non intervention group (NIG). It was
calculated by multiplying the size of a simple randomized
design by the design effect or inflation factor. For the sim-
ple randomized design, accepting an alpha risk of 0.05 and
a beta risk of 0.20 in a bilateral contrast, 59 subjects were
estimated to be required in the first group and 59 in the
second group, to detect a difference greater than or equal
to 28.4% in the screening coverage of the 41.6% in the
NIG. The loss to follow up rate was estimated at 20%. The
calculation of the sample was performed with the Granmo
5.2 computer program for Windows. According to a lit-
erature review [17,18] considering an intraclass correlation
coefficient of 0.05 and a mean number of 3,500 women
from 30 to 70 years of age with incorrect screening in each
Basic Health Care Assistance (BHCA), the design effect
was 176 and thus, 20,768 women who were not appropri-
ately screened needed to be studied.
Randomization process
The cluster unit was each BHCA to avoid a contamin-
ation risk among women in the close geographical areas.This study is based on the Public Primary Health Care
Services SAP Cerdanyola together with the Sexual and
Reproductive Health Program, provided free of charge.
SAP Cerdanyola is divided into five BHCAs, 4 of which
had similar socio-economic characteristics. One BHCA
was excluded because it had a very high socio-economic
status compared to the other 4 BHCA. Each BHCA was
randomly assigned to each arm.
Study arms
Each of the 4 participating centres was assigned to one
study arm each:
1. NIG: includes women opportunistically attending
the clinic. These women were entered into the
routine protocol.
2. IG1(Intervention group 1): a personalized letter was
sent to the participant and signed by the patient’s
primary care physician and professionals from the
corresponding Public Health Center.
3. IG2 (Intervention group 2): the same invitation
letter as that used in the IG1 was sent to the
participant, as well as an informative leaflet on the
prevailing reasons for screening cervical cancer. We
evaluated the repercussion of informed participation.
4. IG3 (Intervention group 3): the same intervention as
the one performed in IG2, complemented by a phone
call 3 days prior to the appointment date indicated in
the invitation letter, as a reminder of the visit.
All the interventions arm received a pre-assigned date
for the screening visit.
Clinical effectiveness measures
The primary outcome measure was the percentage of
women who accepted to be screened and were finally
categorized as adequately screened. The secondary out-
come measures included the total number of cytologies
performed, HPV infections detected, different grades of
cervical intraepithelial lesions detected and cancer de-
tected. The follow up period of this trial finished when
the diagnosis of each screening visit was completed.
Information sources
All participants were given a structured questionnaire to
obtain information related to sociodemographic, medical
and behavioral factors including date of birth, country of
origin, education, job situation, level of income, family
income, marital status, number of children, care-giver to
dependents, type of gynecological care and history of
cervical-uterine disease. We also collected information
on previous screening and, if so, type of medical assist-
ance (private or public), frequency of visits, the result of
the last cytology test performed and previous HPV tests.
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tion groups, all women identified in the control group
characterized as having an incorrect screening were in-
vited to answer the questionnaire via a telephone call. A
review of the participants’ clinical history on the Infor-
mation Systems (eCAP) of the area was also undertaken
to obtain information related to clinical data.
Statistical analysis
Qualitative variables are described with absolute fre-
quencies and percentages. The quantitative variables are
expressed with means and standard deviations. The Chi-
square test was used in the qualitative variables compari-
son, and analysis of variance for the quantitative vari-
ables analysis. The effect size of each study arm was
quantified as the difference in coverage before and after
the intervention. The level of significance used was p ≤
0.05. The analyses were performed with the SPSS statis-
tical package for Windows v. 20.0.
Results
Participation and adherence
A total of 5,820 women aged 60 to 70 years old enrolled in
the Primary Health Care centers were included: 1,489 pa-
tients in IG1, 1,276 in IG2, 2,010 in IG3 and 932 in the
NIG (Figure 1). The screening situation was unknown for
3,616 women in the intervention groups and 665 in theFigure 1 Flowchart of the population sample assigned to the centres
population with no previous screening, the participation achieved anNIG. A response was obtained from 2,560 women after
the intervention, representing an adherence of 70.8%. Ap-
pointments were attended by 724 (68.2%) women in IG1,
678 (73.3%) in IG2, and 1,158 (71.1%) women in IG3. In
the NIG 56 women (8.4%) spontaneously requested a visit
to perform the cytology test.
After identifying women who fulfilled the criteria of
incorrect screening, cervical cancer screening was car-
ried out in 1,376 women (368 from IG1, 403 from IG2
and 605 from IG3). A large proportion of women in the
intervention groups answered the personal questionnaire
during their gynaecological visit (GI173.3%, GI2 68.2%
and GI3 71.1%) while in the control group the tele-
phonic contact was possible in 52% of women identified
with incorrect screening.
Table 1 describes the characteristics of the women
who participated in the personalized interview. Overall,
the average age of the women was 66.2 (SD 4.0) years,
and most were of Spanish origin, with a primary educa-
tion level (32.2%) or incomplete primary education level
(34.9%), while 16.7% had not received any education and
3.1% reported university studies. Most women were mar-
ried (70.8%) and had children (94.6%) and 36.1% of the
women declared having a monthly family income of be-
tween 1,000 to 2,000 euros.
Although most of the participants in all groups re-
ported use of public health care centers for screeningand assigned to each of the intervention study arms, the
d the final coverage obtained in each intervention arm.
Table 1 Sociodemographic characteristics, screening history and reason for non attendance to screening by
intervention activity of the study population
Intervention groups






Letter + leaflet + phone call
(IG3)
Total P
Interviewed 349 724 678 1158º 2909
Age mean (SD) 66.6 (4,1) 66.3 (4,1) 66.1 (4.1) 66.1 (3,9) 66.2 (4.0) 0.029




None 46 (13.4%) 99 (22.1%) 81 (18,1%) 95 (14,0%) 321 (16.7%) <0.001
Incomplete Primary 128 (37.2%) 177 (39.5%) 138 (30,8%) 226 (33,4%) 669 (34.9%)
Primary 110 (32.0%) 130 (29.0%) 151 (33,7%) 226 (33,4%) 617 (32.2%)
High School 54 (15.7%) 35 (7.8%) 58 (12,9%) 103 (15,2%) 250 (13%)
University 6 (1.7%) 7 (1.6%) 20 (4,5%) 27 (4,0%) 60 (3.1%)
Monthly family
income
from 0 to 600€ 76 (30.3) 103 (26.6) 80 (21.4) 94 (16,3) 353 (22.3) <0.001
from 601 to 1000 € 123 (49.0) 126 (32.6) 109 (29.2) 166 (28,9) 524 (33.0)
from 1001 to 2000€ 49 (19.5) 137 (35.4) 149 (39.9) 238 (41.4) 573 (36.1)
more than 2000€ 3 (1.2) 21 (5.4) 35 (9.4) 77 (13.4) 136 (8.6)




0 13 (3.7%) 26 (5.7%) 29 (6.5%) 36 (5.3%) 104 (5.4%) <0.001
1-2 132 (37.8%) 242 (52.7%) 222 (49.4%) 362 (53.4%) 958 (49.5%)
>2 204 (58.5%) 191 (41.6%) 198 (44.1%) 280 (41.3%) 873 (45.1%)
Type of gynecological care
Public 231 (66.8%) 216 (48.0%) 232 (50.7%) 301 (45.1%) 980 (51.0%) <0.001
Private 49 (14.2%) 126 (28.0%) 119 (26.0%) 235 (35.2%) 529 (27.5%)
Mixed 4 (1.2%) 13 (2.9%) 33 (7.2%) 22 (3.3%) 72 (3.7%)
None 62 (17.9%) 95 (21.1%) 74 (16.2%) 110 (16.5%) 341 (17.7%)
Lag time since last Pap screening
1-3 136 (39%) 208 (46.6%) 192 (45.1%) 340 (50.1%) 876 (46.1%) <0.001
4-6 146 (41.8%) 131 (29.4%) 134 (31.5%) 194 (28.6%) 605 (31.9%)
never 67 (19.2%) 107 (24.0%) 100 (23.5%) 144 (21.2%) 418 (22.0%)
Reasons for non-attendance to screening for women with no previous Pap
Fear and dislike 4 (6.0%) 43 (42.2%) 42 (42.4%) 50 (37.0%) 139 (34.5%) <0.001
Uninformed 63 (94.0%) 56 (54.9%) 53 (53.5%) 84 (62.2%) 256 (63.5%)
Other 0 (0.0%) 3 (2.9%) 4 (4.1%) 1 (0.7%) 8 (2.0%)
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neous among the groups, and was particularly low in the
control group (14%) compared to overall (27%).
No type of gynecological care was reported in 17.7% of
all the women. Out of all the women interviewed, 22%
reported no previous cytology and 31.9% stated that the
last cytology was 4 to 6 years before the interview. In al-
most half of the interviews (46.1%) a previous cytologytest was performed within an interval of ≥3 years, al-
though this percentage was significantly higher in IG3
(50.1%), (p < 0.001). Out of the women reporting no pre-
vious screening cytology tests, 63.5% indicated that the
reason for this was lack of knowledge on its importance
and 34.5% reported being afraid or disliking the test.
The analysis of the medical records in the target popula-
tion identified population coverage of 41.6% through the
Acera et al. BMC Women's Health 2014, 14:86 Page 6 of 8
http://www.biomedcentral.com/1472-6874/14/86public health system. After obtaining the information
from the women themselves, cervical cancer screening
coverage prior to our intervention was estimated to be
47.4% (Table 2). This information was unknown for the
control group.
Increase in coverage after the intervention
After carrying out the interventions in each arm, the glo-
bal coverage increased up to 76.2% (with a range between
groups of 74.6% to 79.0%). Thus, the coverage rose by
24.7% in IG1, by 31.6% in IG2 and by 30.1% in IG3. The
difference between IG3 and IG2 was very minor (1.5%)
and more marked (7%) between IG1 and IG2.
Since only 52.5% of the control group answered the
questionnaire about screening practices our estimates on
the real coverage could not be fully estimated.
Cytology results and detection of HPV
A total of 1,376 cytology tests and 920 HPV determina-
tions (HC2) were performed in the intervention groups,
with 99.3% showing negative results. Fifty-five cytology
tests were carried out in the control group, all with
negative results.
Of the 9 positive cytology results, 2 suspected cancers
were detected and histologically confirmed, 3 High Squa-
mous Intraepithelial Lesion (HSIL) and 4 Atypical Squa-
mous Cervical Under Signification (ASC-US).
Twenty-two women were found to be HPV positive, of
which 13 (59.1%) presented negative cytology results. All
the abnormal cytologies were detected in HPV positive
women.
Discussion
This study confirmed that an active search for women to
undergo screening for cervical cancer considerably in-
creased participation rates. According to our results, this
preventive intervention avoided several cases of severe
disease in the population. We decided to use a letter
with a fixed appointment date for the three study arms
because it has been endorsed by different studies [12],
and we could compare this intervention with other
screening strategies as well as with the control group.
We observed that the 3 strategies calling for screeningTable 2 Target population and participation by intervention
Characteristic Letter (IG1) Letter + leaflet (IG2)
Assigned population n = 1489 n = 1276
Initial coverage (*) 763 (51.2%) 605(47.4%)
Final coverage 1131 (76.0%) 1008 (79.0%)
Difference 368 (24.7%) 403(31.6%)
95% CI (22.5-26.9%) (29.0 - 34.1%)
Initial coverage: Women with previous screening in computerized registries plus tho
exclusion (hysterectomy, change in residence, disease at the time of the visit).
CI: Confidence Interval.significantly increased the participation from 47.4% up
to 76.2%. The greatest increase in coverage was obtained
in IG2 (letter + leaflet) compared to IG1 (only the letter).
The addition of a phone call hardly improved the per-
centage of coverage obtained in the IG2.
While among women in the NIG the level of participa-
tion was only 8.4%, all other intervention groups showed
participation levels greater than 68%. This confirms that
a direct intervention, even at advanced ages, increases
the adherence to screening.
Our study is in agreement with previous evaluations
[12,19] supporting that coverage can easily be increased
when there is individual contact with each woman. Al-
though this approach implies organizing screening activ-
ities, in the long run this will have a major impact on
women’s health. In our study, adherence was higher than
that observed in other studies aiming to increase cover-
age using similar types of interventions and in similar
age groups [14]. We do not yet know if these data will
be similar in younger age groups. This work is still in
progress.
It is important to note that the letters were sent by the
family physician and the coordinators of the Public
Health Center who in general were professionals known
by the target population. In the letter it was indicated
that the screening visit would be performed by a woman
and the time and day of the appointment was specified,
thereby facilitating the subsequent visit [13].
Different studies have reported that the key question
influencing participation is the precision of the registries
[12,13]. The tools used in the present study were the
eCAP and the information system of the Catalan Public
Health System which is continuously updated.
Our intervention not only increased screening coverage
but also, with the prevailing protocol, allowed women who
were not appropriately screened for cervical cancer to
benefit from a co-test with cervical cytology and HPV.
Both tests provided a very high negative predictive value
for women with negative results thereby allowing these
women to avoid being called up for posterior cervical
screening. In contrast, 9 cases of CIN2+ were detected, 2
undergoing a hysterectomy for grade 1 cancer. If these
women had not been identified, their cancer could haveactivity
Letter + leaflet + phone call (IG3) Total intervention groups
n = 2010 n = 4775
894(44.5%) 2262(47.4%)
1499 (74.6%) 3638(76.2%)
605 (30.1%) 1376 (28.8%)
(28.1 - 32.1%) (27.5 - 30.1%)
se reported to have been correctly screened or presenting reasons for
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Thus these data although based on a limited number of
observations, allowed the identification of 100-fold more
pathology than what would have been expected in the
general population of the same age [14], where the inci-
dence of invasive cervical cancer is estimated to be 7.3 per
100,000 (1).
A low detection of HPV was confirmed in the elderly
women. This result is similar to those obtained in other
studies [20] confirming that women of this age belong to
highly monogamous cohorts or have had time to eliminate
the potential infection. In this elderly cohort, all patho-
logical cytologies were also HPV positive. In addition, 13
women were HPV positive but with a negative cytology
and remain under surveillance.These data indicate that for
women aged 60 to 70, screening by the HPV and cervical
cytology as a triage test is a very good strategy for captur-
ing CIN2+ lesions (through positive results). At present,
the protocol of the Department of Health of the Generali-
tat of Catalonia recommends the use of co-testing with cy-
tology and HPV in women over 39 years who are not
appropriately screened. Considering the results obtained
in the present study, if primary screening was based on
HPV detection and cytology as a triage test, only 19 cytol-
ogies would have been necessary in addition to the HPV
tests. If the results of HPV are negative the screening con-
trols of this elderly cohort should be finalized.
There were some limitations when interpreting our data.
One limitation is that private medical care is rarely regis-
tered in the public health system although it is recom-
mended therefore the information on the private medical
practice was obtained through personal interviews but was
not verified. Another limitation is that the control group
was interviewed via telephone and the response rate was
significantly lower compared to the intervention groups.
This difference could affect the comparison of screening
coverage prior to intervention. Moreover it could be spec-
ulated that individual randomization could have been a
better option to control for co-factors affecting screen-
ing uptake. However, the geographical areas selected for
randomization were chosen to avoid ‘contamination’ be-
tween our intervention groups by clearly separating
them geographically. Finally, it was surprising that the
introduction of a telephone call did not substantially in-
crease coverage. Although we had several trained call
operators a reluctance to answer the phone or to accept
a short conversation seems to be a major obstacle, due
to the overuse of this communication pathway by com-
mercial purposes.
Conclusions
Our cervical cancer intervention study among inappro-
priately screened women found that: 1) actively arran-
ging appointments through a letter with a pre-assignedmedical visit significantly increased participation rates,
2) including an informative leaflet with the letter achieved
the greatest level of participation as well as a greater final
coverage, and 3) a lack of information was the main rea-
son for not attending screening visits.
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